Loading news...
ABBV stock falls 3% in a month amid takeover rumor denials, but Skyrizi and Rinvoq momentum and a deep pipeline support staying invested.
AbbVie said on Monday it would partner with RemeGen to develop an experimental treatment for solid tumors in a deal worth up to $4.95 billion, including milestones.
- RC148 is a novel PD-1/VEGF bispecific antibody being evaluated in multiple advanced solid tumors including certain lung cancers NORTH CHICAGO, Ill. and YANTAI, China, Jan. 12, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) and RemeGen today announced an exclusive licensing agreement for the development, manufacturing and commercialization of RC148, a novel investigational Programmed Cell Death-1 (PD-1)/Vascular Endothelial Growth Factor (VEGF)-targeted bispecific antibody.
Milestone marks progress against AbbVie's previously announced commitment to invest more than $10 billion of capital in the U.S. over the next decade to broadly support innovation and expand critical manufacturing capabilities and capacity Supports production of AbbVie's current and next-generation immunology and neuroscience medicines Transaction anticipated to close in mid-2026 NORTH CHICAGO, Ill., Jan. 12, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and West Pharmaceutical Services (NYSE: WST) announced today a definitive agreement for AbbVie to acquire a device manufacturing facility in Tempe, Arizona and associated intellectual property from West.
EXTON, Pa., Jan. 12, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that the company has reached a definitive agreement to sell all manufacturing and supply rights for SmartDose® 3.5mL On-Body Delivery System and associated facilities to AbbVie (NYSE: ABBV) for total consideration of $112.5 million at close, subject to working capital and other adjustments. The definitive agreement, which is subject to certain closing conditions, is expected to close in mid-2026.
Tempus AI (NASDAQ: TEM) stock rose after releasing preliminary Q4 and 2025 results, with revenue of $1.27B in 2025 and $367M in Q4.
AbbVie is a Dividend King in growth mode. Enbridge offers an attractive dividend plus both safety and growth potential.
MoneyShow presents top investment ideas for 2026 from their contributors. This year's edition presents a mix of metals plays, financial stocks, deep value names, high-octane growth and tech stocks, and beaten-down REITs that offer solid income and turnaround potential. Part 1 of this series includes AbbVie, Alexandria Real Estate Equities, Arbor Realty Trust, Archer Aviation, and Ares Management Corp., among others.
AbbVie and Johnson & Johnson have resilient, noncyclical businesses. They are also outstanding dividend payers.
Merck (MRK) is reportedly in talks to acquire Revolution Medicines (RVMD) for $28-$32 billion or more. This acquisition aims to strengthen MRK's oncology pipeli
ABBV's Q4 outlook hinges on surging Skyrizi and Rinvoq demand, as investors watch immunology sales to offset Humira's past loss of exclusivity.
Stock News xAI under fire over Grok image edits: Elon Musk's xAI (private) restricted Grok's image generation/editing on X to paying users after the tool was us
Clear Harbor Asset Management LLC trimmed its position in shares of AbbVie Inc. (NYSE: ABBV) by 7.7% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 33,583 shares of the company's stock after selling 2,797 shares during the period. Clear Harbor Asset Management LLC's
Ferguson Wellman Capital Management Inc. increased its position in AbbVie Inc. (NYSE: ABBV) by 0.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 647,685 shares of the company's stock after acquiring an additional 3,260 shares during the period. AbbVie makes
Duncker Streett and Co. Inc. lifted its position in AbbVie Inc. (NYSE: ABBV) by 17.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 71,277 shares of the company's stock after buying an additional 10,721 shares during the
Pharmaceuticals giant, Merck and Co. Inc. (NYSE: MRK), is reportedly in talks to acquire cancer drug-maker Revolution Medicines Inc. (NASDAQ: RVMD) in a deal potentially valued at between $28 and $32 billion.
AbbVie Inc. maintains its Hold rating, as its latest dividend raise signals near-term earnings pressure and a decelerating growth trend. ABBV's Q1 2026 dividend increases 5.5% YOY, lagging both its past growth rates and the healthcare sector median. Current valuation appears stretched, with ABBV stock trading at 23.5x P/E and a PEGY ratio of 1.41x.
Shareholders in both drugmakers appear disappointed that a deal may not happen.
Trump puts pressure on defense contractors, Globus Medical soars on preliminary results, and more
CX Institutional lifted its holdings in AbbVie Inc. (NYSE: ABBV) by 30.8% in the undefined quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 85,402 shares of the company's stock after purchasing an additional 20,097 shares during the quarter. CX Institutional's holdings in AbbVie were